Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 28891408

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
N Engl J Med
Publication date
2017 Nov 9
First author
Long GV

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2017 Nov;14(11):647. doi: 10.1038/nrclinonc.2017.159.
    note
    Source null
    related pmid
    28948976
    relationship
    Comment in
  2. citation
    N Engl J Med. 2017 Nov 9;377(19):1888-1890. doi: 10.1056/NEJMe1711199.
    note
    Source null
    related pmid
    29117487
    relationship
    Comment in
  3. citation
    N Engl J Med. 2018 Feb 15;378(7):678. doi: 10.1056/NEJMc1716071.
    note
    Source null
    related pmid
    29446283
    relationship
    Comment in
  4. citation
    Br J Dermatol. 2018 Apr;178(4):817-820. doi: 10.1111/bjd.16347.
    note
    Source null
    related pmid
    29668089
    relationship
    Comment in
  5. citation
    N Engl J Med. 2019 Apr 4;380(14):1374-1376. doi: 10.1056/NEJMc1902228.
    note
    Source null
    related pmid
    30943345
    relationship
    Comment in

Authors and identifiers

  1. name
    Long GV
    type
    Author
  2. name
    Hauschild A
    type
    Author
  3. name
    Santinami M
    type
    Author
  4. name
    Atkinson V
    type
    Author
  5. name
    Mandalà M
    type
    Author
  6. name
    Chiarion-Sileni V
    type
    Author
  7. name
    Larkin J
    type
    Author
  8. name
    Nyakas M
    type
    Author
  9. name
    Dutriaux C
    type
    Author
  10. name
    Haydon A
    type
    Author
  11. name
    Robert C
    type
    Author
  12. name
    Mortier L
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Long GV
    type
    Author
  2. name
    Hauschild A
    type
    Author
  3. name
    Santinami M
    type
    Author
  4. name
    Atkinson V
    type
    Author
  5. name
    Mandalà M
    type
    Author
  6. name
    Chiarion-Sileni V
    type
    Author
  7. name
    Larkin J
    type
    Author
  8. name
    Nyakas M
    type
    Author
  9. name
    Dutriaux C
    type
    Author
  10. name
    Haydon A
    type
    Author
  11. name
    Robert C
    type
    Author
  12. name
    Mortier L
    type
    Author
bibliography ids
  1. nci-bib-e54fee59e43831ae7cd6b44b
book metadata
content sha256
4ae6ae1a00bf2c2816818e38a8f068cd36bd0cc1b21cdd01514640de5f4ede08
document type
citation
dois
  1. 10.1056/NEJMoa1708539
electronic publication date
display
2017 Sep 10
precision
day
year
2017
evidence scope
bibliographic_metadata_only
id
pubmed:28891408
immutable id
pubmed:28891408@4ae6ae1a00bf2c2816818e38a8f068cd36bd0cc1b21cdd01514640de5f4ede08
journal
abbreviation
N Engl J Med
issn electronic
1533-4406
issn print
0028-4793
issue
19
name
The New England journal of medicine
nlm unique id
0255562
pages
1813-1823
volume
377
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2017 Nov;14(11):647. doi: 10.1038/nrclinonc.2017.159.
    note
    Source null
    related pmid
    28948976
    relationship
    Comment in
  2. citation
    N Engl J Med. 2017 Nov 9;377(19):1888-1890. doi: 10.1056/NEJMe1711199.
    note
    Source null
    related pmid
    29117487
    relationship
    Comment in
  3. citation
    N Engl J Med. 2018 Feb 15;378(7):678. doi: 10.1056/NEJMc1716071.
    note
    Source null
    related pmid
    29446283
    relationship
    Comment in
  4. citation
    Br J Dermatol. 2018 Apr;178(4):817-820. doi: 10.1111/bjd.16347.
    note
    Source null
    related pmid
    29668089
    relationship
    Comment in
  5. citation
    N Engl J Med. 2019 Apr 4;380(14):1374-1376. doi: 10.1056/NEJMc1902228.
    note
    Source null
    related pmid
    30943345
    relationship
    Comment in
outcomes validated
false
pmid
28891408
provenance
batch id
fb25b16edcb1373b70c1
provider
NCBI PubMed ESummary
record sha256
da6dc3cf230160ec25370283c113f8dc56e6ce12f2478d1fc8d1bc5831a6a6d1
response sha256
182c99bf1974b58308315b66aa28d31c61e8fc31cf3de4cadb0340a4f6734c52
retrieved at
2026-09-09T23:47:28.490065+00:00
publication date
display
2017 Nov 9
precision
day
year
2017
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/28891408/
title
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.

Preserved source evidence · Not medical advice